Literature DB >> 27888679

Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014.

Amanda-Louise Fenger Carlander1, Christian Grønhøj Larsen1, David Hebbelstrup Jensen1, Emilie Garnæs1, Katalin Kiss2, Luise Andersen2, Caroline Holkmann Olsen3, Maria Franzmann4, Estrid Høgdall5, Susanne K Kjær6, Bodil Norrild7, Lena Specht8, Elo Andersen9, Thomas van Overeem Hansen10, Finn Cilius Nielsen10, Christian von Buchwald11.   

Abstract

BACKGROUND: Human papillomavirus (HPV) is a critical element in the rising incidence of oropharyngeal squamous cell carcinoma (OPSCC), although whether this trend will continue, and the types of HPV responsible, are currently unknown. We previously demonstrated an increased incidence of HPV-related OPSCC in the high HPV prevalence area of Eastern Denmark from 2000 to 2010. Therefore, we investigated if the incidence for OPSCC continued to rise, the association to HPV and putative HPV-types in Eastern Denmark from 2011 to 14. We then projected the expected incidence of OPSCC versus cervical cancer through to 2020. PATIENTS AND METHODS: Patients with OPSCC (tonsillar squamous cell carcinoma [TSCC] and base of tongue squamous cell carcinoma [BSCC]) were identified via the Danish Head and Neck Cancer Group and the Danish Pathology Databank (n = 700). Tumours were re-reviewed and assessed using p16 immunohistochemistry, HPV DNA polymerase chain reaction (PCR), with genotyping by next generation sequencing.
RESULTS: Sixty-two percent (432/700) of tumours were HPV-positive (HPV+). The total incidence rate (per 100.000) for OPSCC increased from 4.0 in 2011 to 4.5 in 2014, primarily due to a rise in HPV+ TSCCs and HPV+ BSCCs, although numbers of HPV-negative (HPV-) OPSCC also increased during the study period. The majority of HPV+ tumours were HPV16 DNA positive (86%), but we also identified HPV33 DNA (6%), HPV35 DNA (4%) and others (3%), including HPV18, 26, 31, 45, 56, 58, 59 and HPV67.
CONCLUSION: An increasing incidence of OPSCC is driven primarily by HPV+ OPSCC. Sixty-two percent of tumours were HPV+, which is a high-prevalence, although the lower number of HPV- cases has yet to stabilise. HPV16 was the predominant genotype, although a significant proportion (14%) was of another genotype. Our projections suggest that the number of HPV+ OPSCC will exceed that of cervical cancer in 2016 in Eastern Denmark.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Base of tongue; Genotype; HPV; HPV16; Incidence; Oropharynx; Tonsillar; p16

Mesh:

Year:  2016        PMID: 27888679     DOI: 10.1016/j.ejca.2016.10.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

1.  Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined.

Authors:  Xiuning Le; Ehab Y Hanna
Journal:  Ann Transl Med       Date:  2018-06

Review 2.  Leveraging Genomics for Head and Neck Cancer Treatment.

Authors:  J D Kemmer; D E Johnson; J R Grandis
Journal:  J Dent Res       Date:  2018-02-08       Impact factor: 6.116

3.  High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.

Authors:  Jean-Luc Prétet; Véronique Dalstein; Antoine Touzé; Agnès Beby-Defaux; Patrick Soussan; Élise Jacquin; Philippe Birembaut; Christine Clavel; Christiane Mougin; Alexandra Rousseau; Jean Lacau Saint Guily
Journal:  Clin Exp Med       Date:  2022-02-23       Impact factor: 3.984

Review 4.  Epidemiology of HPV Related Malignancies.

Authors:  Nicholas Scott-Wittenborn; Carole Fakhry
Journal:  Semin Radiat Oncol       Date:  2021-10       Impact factor: 5.421

5.  Prognostic factors for human papillomavirus-positive and negative oropharyngeal carcinomas.

Authors:  Linda X Yin; Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni M Rettig; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; David W Eisele; Carole Fakhry
Journal:  Laryngoscope       Date:  2018-03-14       Impact factor: 3.325

6.  Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer.

Authors:  Virginia E Drake; Carole Fakhry; Melina J Windon; C Matthew Stewart; Lee Akst; Alexander Hillel; Wade Chien; Patrick Ha; Brett Miles; Christine G Gourin; Rajarsi Mandal; Wojciech K Mydlarz; Lisa Rooper; Tanya Troy; Siddhartha Yavvari; Tim Waterboer; Nicole Brenner; David W Eisele; Gypsyamber D'Souza
Journal:  Cancer       Date:  2021-01-11       Impact factor: 6.860

Review 7.  Integration of Human Papillomavirus Genomes in Head and Neck Cancer: Is It Time to Consider a Paradigm Shift?

Authors:  Iain M Morgan; Laurence J DiNardo; Brad Windle
Journal:  Viruses       Date:  2017-08-03       Impact factor: 5.048

8.  Cause-specific mortality in HPV+ and HPV- oropharyngeal cancer patients: insights from a population-based cohort.

Authors:  Cecilie Nørregaard; Christian Grønhøj; David Jensen; Jeppe Friborg; Elo Andersen; Christian von Buchwald
Journal:  Cancer Med       Date:  2017-11-24       Impact factor: 4.452

9.  FDG-PET/CT identified distant metastases and synchronous cancer in squamous cell carcinoma of the head and neck: the impact of smoking and P16-s.

Authors:  Mogens Bernsdorf; Annika Loft; Anne Kiil Berthelsen; Julie Kjems; Ivan Richter Vogelius; Christian von Buchwald; Claus Andrup Kristensen; Anita Birgitte Gothelf; Jeppe Friborg
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-01       Impact factor: 2.503

10.  Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer.

Authors:  Cheng-Chih Huang; Yu-Chu Su; Chan-Chi Chang; Wei-Ting Lee; Chun-Yen Ou; Yuan-Hua Wu; Shang-Yin Wu; Yu-Hsuan Lai; Jehn-Shyun Huang; Ken-Chung Chen; Wei-Ting Hsueh; Sen-Tien Tsai; Chia-Jui Yen; Jang-Yang Chang; Mei-Ling Tsai; Chen-Lin Lin; Ya-Ling Weng; Han-Chien Yang; Yu-Shan Chen; Jenn-Ren Hsiao; Jeffrey S Chang
Journal:  Cancer Med       Date:  2021-05-04       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.